Lilly to invest 5. 3 billion in Indiana

To meet astronomical demand for its weight-loss and antidiabetes drugs, Eli Lilly and Company says it will double its investment at a drug active-ingredient manufacturing site now under construction in Lebanon, Indiana. The company will inject an additional 5. 3 billion, increasing its total investment in the site to 9 billion. The expansion will boost the production of tirzepatide, the peptide-based active pharmaceutical ingredient (API) used in Zepbound and Mounjaro, weight-loss and antidiabetes medicines that the US Food and Drug Administration approved in 2023 and 2022, respectively. Construction of the Indiana facility began in 2023. Lilly expects to start manufacturing at the site in 2026 and says it will increase production over the subsequent years. Once the facility is fully operational, it will employ 900 workers, including engineers, scientists, operating personnel, and lab technicians. Since 2020, Lilly says, it has committed to spending 16 billion on new manufacturing sites in the